BMY

Bristol-Myers Squibb Co

Feb 20 • 11:06AM ET

60.30

-0.00 -0.01 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN-D NVS

| Held by: VTI SCHD VOO IVV SPY VTV XLV JEPI VYM COWZ

Index	S&P 500	P/E	17.43	EPS (ttm)	3.46	Insider Own	0.18%	Shs Outstand	2.04B	Perf Week	0.73%
Market Cap	122.79B	Forward P/E	9.94	EPS next Y	6.07	Insider Trans	-1.50%	Shs Float	2.03B	Perf Month	10.64%
Enterprise Value	159.29B	PEG	-	EPS next Q	1.43	Inst Own	81.98%	Short Float	1.47%	Perf Quarter	28.13%
Income	7.05B	P/S	2.55	EPS this Y	0.94%	Inst Trans	1.87%	Short Ratio	2.07	Perf Half Y	24.94%
Sales	48.19B	P/B	6.65	EPS next Y	-2.30%	ROA	7.72%	Short Interest	29.89M	Perf YTD	11.78%
Book/sh	9.07	P/C	11.50	EPS next 5Y	-4.28%	ROE	40.53%	52W High	63.33 -4.79%	Perf Year	8.08%
Cash/sh	5.24	P/FCF	9.56	EPS past 3/5Y	5.47% -	ROIC	11.17%	52W Low	42.52 41.81%	Perf 3Y	-15.21%
Dividend Est.	2.52 (4.18%)	EV/EBITDA	8.28	Sales past 3/5Y	1.45% 2.54%	Gross Margin	65.89%	Volatility	2.21% 2.29%	Perf 5Y	-0.50%
Dividend TTM	2.49 (4.13%)	EV/Sales	3.31	EPS Y/Y TTM	178.35%	Oper. Margin	31.36%	ATR (14)	1.37	Perf 10Y	-5.49%
Dividend Ex-Date	Jan 02, 2026	Quick Ratio	1.14	Sales Y/Y TTM	-0.22%	Profit Margin	14.64%	RSI (14)	63.20	Recom	2.40
Dividend Gr. 3/5Y	4.37% 6.24%	Current Ratio	1.26	EPS Q/Q	-55.76%	SMA20	3.73%	Beta	0.28	Target Price	60.91
Payout	71.98%	Debt/Eq	2.55	Sales Q/Q	11.62%	SMA50	7.99%	Rel Volume	0.62	Prev Close	60.30
Employees	32500	LT Debt/Eq	2.42	Earnings	Feb 05 BMO	SMA200	22.93%	Avg Volume	14.45M	Price	60.30
IPO	Jul 05, 1929	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.77% 1.80%	Trades		Volume	2,536,625	Change	-0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Barclays	Overweight	$75
Jan-07-26	Upgrade	UBS	Neutral → Buy	$65
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy	$61
Dec-12-25	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-13-25	Initiated	Scotiabank	Sector Perform	$45
Aug-05-25	Downgrade	Daiwa Securities	Outperform → Neutral	$42
Apr-22-25	Initiated	Piper Sandler	Overweight
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$55
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55

Show Previous Ratings

Today 08:08AM	Barclays launches U.S. biopharma coverage with four preferred picks (Investing.com)
07:59AM	Here Are Fridays Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More (24/7 Wall St.)
Feb-19-26 09:54AM	What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? (Insider Monkey)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
10:01AM	BioArctic AB (BRCTF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Partnerships ... (GuruFocus.com)
09:32AM	Loading…
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
05:35AM	FDA accepts BMS protein degrader for review; Disc rare disease drug rejected (BioPharma Dive)
Feb-17-26 09:21PM	This State Has More Millionaires Per Capita Than Any Other (24/7 Wall St.)
10:00AM	Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026? (Zacks)
06:59AM	U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma (Business Wire)
Feb-16-26 11:45AM	Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period (Zacks)
09:54AM	Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? (Zacks)
05:00AM	Theranostics earmarked as the future of radiopharmaceuticals (Pharmaceutical Technology)
Feb-13-26 09:57AM	Here's What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) (Insider Monkey)
Feb-12-26 12:37PM	This Is Gracos Dividend Score After Paying Investors (24/7 Wall St.)
04:42AM	Loading…
04:42AM	Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth (Insider Monkey)
12:38AM	The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb's Q4 Earnings Call (StockStory)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
09:00AM	Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-10-26 11:06AM	Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line? (Zacks)
07:00AM	These Low IV Stocks May Be Setting Up for an Explosive Move (Barchart)
Feb-09-26 10:29AM	BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? (Zacks)
08:35AM	Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating (Insider Monkey)
Feb-07-26 10:45AM	Bristol Myers price target raised to $40 from $37 at Morgan Stanley (TipRanks)
10:08AM	Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug (Insider Monkey)
Feb-06-26 07:35AM	Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. (Barrons.com)
06:48AM	BMS reports flat revenue growth for full-year 2025 (Pharmaceutical Technology)
04:27AM	Bristol Myers Squibb Q4 Earnings Call Highlights (MarketBeat)
12:34AM	BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus (StockStory)
Feb-05-26 04:31PM	Bristol Myers Expects Sales To Decline This Year; So Why Is The Stock Rising? (Investor's Business Daily)
02:46PM	Loading…
02:46PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
02:04PM	Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ... (GuruFocus.com)
01:29PM	Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. (Barrons.com)
11:08AM	Weekly Jobless Claims Exceed Expectations (Zacks)
10:50AM	Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasnt Even Hit Yet (24/7 Wall St.)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
10:32AM	Jobless Claims Pop Up a Bit, Major Morning for Earnings (Zacks)
10:25AM	Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. (Barrons.com)
10:07AM	Bristol Myers Flags Data-Rich 2026 After Solid Quarter (Benzinga)
09:57AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
09:30AM	Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:04AM	These Stocks Are Todays Movers: Alphabet, Strategy, Qualcomm, Broadcom, Estee Lauder, Bristol Myers, Amazon, and More (Barrons.com)
08:51AM	Bristol Myers Rises Inside A Buy Zone On Street-Beating 2026 Outlook (Investor's Business Daily)
08:14AM	Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025 (StockStory)
08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:17AM	Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. (Barrons.com)
07:09AM	Bristol Myers: Q4 Earnings Snapshot (Associated Press Finance)
07:09AM	Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth (The Wall Street Journal)
06:59AM	Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 (Business Wire)
04:59AM	Amazon.com headlines earnings slate (MarketWatch)
04:18AM	Stock Market Today: Dow, S&P 500 and Nasdaq mixed as AI spending and disruption weigh on tech sector after Alphabet results; silver dives; bitcoin falls near 70k; Amazon.com earnings on tap. (MarketWatch)
Feb-04-26 07:00PM	Amazon earnings, Fed commentary, mortgage rates: What to Watch (Yahoo Finance Video)
01:40PM	What's Going On With Bristol-Myers Squibb Stock Today? (Benzinga)
07:05AM	GSK (GSK) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:59AM	Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi (Business Wire)
Feb-03-26 10:10PM	Bristol-Myers Squibb Earnings: What To Look For From BMY (StockStory)
11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
06:59AM	Bristol Myers Squibb Introduces 'Change the Target. Change Whats Possible. to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care (Business Wire)
05:12AM	Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead (Insider Monkey)
Feb-02-26 07:28PM	Bristol-Myers Squibb Company (BMY): A Bull Case Theory (Insider Monkey)
11:12AM	Market Awaits January Manufacturing Numbers (Zacks)
10:35AM	Six More Weeks of Q4 Earnings Season? (Zacks)
10:25AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
10:00AM	iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:15AM	Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)
08:10AM	Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? (Zacks)
Feb-01-26 01:27PM	Piper Sandler Raises Bristol Myers (BMY) PT to $66 Citing Pipeline Visibility (Insider Monkey)
07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-30-26 05:10PM	Citi Raises Bristol-Myers (BMY) Target as Sector Outlook Improves into 2026 (Insider Monkey)
08:49AM	Will BMY's Oncology Collaborations Drive Its Next Growth Phase? (Zacks)
07:20AM	3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year (Motley Fool)
03:00AM	How Big Pharma is navigating a $300 billion patent cliff (Pharma Voice)
Jan-29-26 10:02PM	Piramal Pharma Ltd (BOM:543635) Q3 2026 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
10:00AM	Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for (Zacks)
02:07AM	Bristol Myers Squibb (BMY), Microsoft (MSFT) Partner to Enhance Early Lung Cancer Detection Through AI (Insider Monkey)
Jan-28-26 05:45PM	Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
10:49AM	The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears (Pharmaceutical Technology)
09:48AM	Some of Pharma's Biggest Brands Face a New Reality (GuruFocus.com)
05:51AM	Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle (Benzinga)
05:21AM	Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Jan-27-26 06:09PM	Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy (Insider Monkey)
Jan-26-26 09:00AM	Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know (Zacks)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-23-26 06:50PM	AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. (Motley Fool)
01:05PM	Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? (Motley Fool)
07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
01:30AM	AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next. (Barrons.com)
Jan-22-26 02:02PM	Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million (Benzinga)
01:01PM	BMS bets on Januxs novel solid tumour therapy through $850m deal (Pharmaceutical Technology)
09:15AM	Is BMY's Deep Pipeline the Key to Its Next Growth Phase? (Zacks)
07:00AM	Bristol Myers buys into Januxs masked T cell engagers (BioPharma Dive)
Jan-21-26 09:47PM	Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery (Insider Monkey)
12:05PM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
07:24AM	Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences (Benzinga)
07:10AM	Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026 (Insider Monkey)
Jan-20-26 02:45PM	Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock (Insider Monkey)
01:41PM	BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? (Zacks)
01:02PM	Bristol Myers, Microsoft Aim To Catch Lung Cancer Early With New AI Tool (Benzinga)
08:58AM	Profit Alert: Netflix Goes All-Cash, Microsoft Cracks Healthcare AI, and How You Win (24/7 Wall St.)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '26	Option Exercise	0.00	2,543	0	22,261	Feb 03 04:40 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '26	Option Exercise	0.00	10,079	0	18,868	Feb 03 04:39 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	2,964	0	2,964	Nov 04 05:18 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Nov 01 '25	Option Exercise	0.00	6,281	0	22,383	Nov 04 05:15 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Nov 01 '25	Option Exercise	0.00	6,281	0	20,078	Nov 04 05:13 PM
Gallman Cari	EVP, General Counsel	Oct 02 '25	Option Exercise	0.00	4,558	0	13,398	Oct 06 05:22 PM
Elkins David V	EVP, Chief Financial Officer	Sep 02 '25	Sale	47.33	56,000	2,650,480	167,379	Sep 03 06:46 PM
Short Bartie Wendy	EVP, Corporate Affairs	Sep 01 '25	Option Exercise	0.00	1,235	0	6,301	Sep 03 06:42 PM
Elkins David V	Officer	Sep 02 '25	Proposed Sale	47.30	56,000	2,648,800		Sep 02 11:16 AM
Gallman Cari	EVP, General Counsel	Aug 01 '25	Option Exercise	0.00	1,061	0	9,383	Aug 05 06:01 PM
Short Bartie Wendy	EVP, Corporate Affairs	Aug 02 '25	Option Exercise	0.00	738	0	5,444	Aug 05 05:58 PM
Short Bartie Wendy	EVP, Corporate Affairs	Aug 02 '25	Sale	44.23	378	16,719	5,066	Aug 05 05:58 PM
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '25	Option Exercise	0.00	8,040	0	8,040	Jun 04 05:37 PM
Hickey Benjamin	President, RayzeBio Org.	May 09 '25	Sale	38.01	97	3,702	0	May 13 07:03 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Apr 25 '25	Buy	47.58	4,250	202,215	83,513	Apr 29 06:14 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '25	Option Exercise	0.00	3,306	0	15,489	Apr 03 05:15 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '25	Option Exercise	0.00	11,255	0	20,148	Mar 12 09:39 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '25	Option Exercise	0.00	23,150	0	26,937	Mar 12 09:37 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Mar 10 '25	Option Exercise	0.00	20,423	0	22,339	Mar 12 09:35 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '25	Option Exercise	0.00	16,684	0	20,017	Mar 12 09:34 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '25	Option Exercise	0.00	7,164	0	8,546	Mar 12 09:32 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '25	Option Exercise	0.00	48,718	0	386,496	Mar 12 09:32 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '25	Option Exercise	0.00	7,446	0	7,920	Mar 12 09:31 PM
Holzer Phil M	SVP and Controller	Mar 10 '25	Option Exercise	0.00	7,140	0	17,870	Mar 12 09:31 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '25	Option Exercise	0.00	44,098	0	99,040	Mar 12 09:30 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '25	Option Exercise	0.00	7,588	0	11,626	Mar 12 09:29 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '25	Option Exercise	0.00	69,517	0	252,608	Mar 12 09:28 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '25	Option Exercise	0.00	60,034	0	152,898	Mar 12 09:27 PM
Hickey Benjamin	President, RayzeBio Org.	Mar 01 '25	Option Exercise	0.00	3,286	0	10,419	Mar 04 05:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMY

Bristol-Myers Squibb Co

Upgrade your FINVIZ experience